Bausch & Lomb Recalls Sodium Chloride Ophthalmic Ointment Due to Crystallization
Bausch & Lomb is recalling 35,253 tubes of Sodium Chloride Hypertonicity Ophthalmic Ointment, 5%, due to crystal precipitate formation causing a gritty sensation in the eye.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, and the hazard involves physical irritation (gritty sensation) without reports of serious injury or death, fitting the criteria for a moderate severity recall.
Plain-English summary
Bausch & Lomb, Inc. is recalling 35,253 tubes of Sodium Chloride Hypertonicity Ophthalmic Ointment, 5%, 1/8 oz. (3.5 g) tube per carton. The product is distributed by Major Pharmaceuticals and is identified by NDC 0904-5315-38 and UPC 3 09045 31538 5.
The recall was initiated due to crystal precipitate formation and an increase in complaints associated with a gritty, sand-like feeling in the eye. The affected lots are 159101 (Exp 02/15), 169271 (Exp 09/15), and 170481 (Exp 10/15).
The product was distributed nationwide, as well as in Puerto Rico, Canada, and Hong Kong. Consumers should stop using the product and contact their healthcare provider or the recalling firm for instructions on return or disposal.
The recalled product
- Product
- Sodium Chloride Hypertonicity Ophthalmic Ointment, 5%, 1/8 oz. (3.5 g) tube per carton, Distributed by Major Pharmaceuticals, 31778 Enterprise Drive, Livonia, MI 48150, NDC 0904-5315-38, UPC 3 09045 31538 5.
- Manufacturer
- Bausch & Lomb, Inc.
- Category
- Drug — Ophthalmic
- Affected units
- 35,253
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot #'s: 159101
- Exp 02/15
- 169271
- Exp 09/15
- and 170481
- Exp 10/15
Distribution
Part of a larger recall action
This product is one of 2 recalled by Bausch & Lomb, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Bausch & Lomb, Inc.
See all →- HighBausch + Lomb Stellaris Elite Vit Cutter Back Cap Separation Recall
FDA (Devices) · 2018-10-03
- HighBausch + Lomb Stellaris Elite Vit Cutter Recall Due to Cap Separation
FDA (Devices) · 2018-10-03
- HighBausch + Lomb Stellaris Elite Vit Cutter Recall for Back Cap Separation
FDA (Devices) · 2018-10-03
- HighBausch + Lomb Stellaris Elite Vit Cutter Recall for Cap Separation
FDA (Devices) · 2018-10-03
- HighBausch + Lomb Stellaris Elite Vit Cutter Recall Due to Cap Separation
FDA (Devices) · 2018-10-03
Same hazard · crystallization
See all →- SeverePar Health Recalls Buprenorphine Hydrochloride Injection Due to Crystallization
FDA (Drugs) · 2026-10-07
- ModerateCyproheptadine Hydrochloride Syrup Recall Due to Precipitate
FDA (Drugs) · 2026-07-29
- HighBuprenorphine injection vials show crystallization identified as buprenorphine free base
FDA (Drugs) · 2026-06-24
- ModerateDapsone Gel Recalled Nationwide for Crystallization
FDA (Drugs) · 2025-01-08
- HighDapsone Topical Gel Recalled Due to Crystallization Defect
FDA (Drugs) · 2025-01-08
Similar recalls
- ModerateSodium Chloride Ophthalmic Ointment Recalled for Manufacturing Deviations
FDA (Drugs) · 2023-01-25
- LowAkorn Recalls Sodium Chloride Ophthalmic Ointment Due to Particulate Matter
FDA (Drugs) · 2020-03-04
- LowBausch & Lomb Recalls Cyclopentolate Hydrochloride Ophthalmic Solution for Labeling Errors
FDA (Drugs) · 2016-02-03
- HighSodium Chloride Ophthalmic Ointment Recalled for Turbidity and Sterility Concerns
FDA (Drugs) · 2022-09-14
- SevereSodium Chloride Ophthalmic Solution Recalled for Sterility Assurance Issues
FDA (Drugs) · 2026-09-30
- SevereWalgreens Sodium Chloride Ophthalmic Ointment Recalled for Sterility Concerns
FDA (Drugs) · 2019-11-27